ClinicalTrials.gov
ClinicalTrials.gov Menu

Prolonged Daily Temozolomide for Low-Grade Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00165360
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : November 2, 2009
Sponsor:
Collaborators:
Schering-Plough
Brigham and Women's Hospital
University of Virginia
Information provided by:
Dana-Farber Cancer Institute

Brief Summary:
The purpose of this trial is to determine the effects (good and bad) temozolomide has on patients with low-grade glioma. It will also determine whether temozolomide is effective in preventing or delaying future tumor growth.

Condition or disease Intervention/treatment Phase
Glioma Astrocytoma Oligodendroglioma Drug: Temozolomide Phase 2

Detailed Description:
  • Treatment with temozolomide is based upon an 11-week cycle (7 weeks on the drug and 4 weeks off). Patients will receive temozolomide once daily for 49 days, then have 28 days without taking temozolomide.
  • Every two to four weeks a physical and neurological examination and blood work will be performed. A magnetic resonance imaging (MRI) scan of the patient's brain will be done approximately every three months (before each cycle of treatment).
  • Treatment may continue for a maximum of a year and a half based on 6 eleven-week cycles. The actual duration of therapy will depend upon the response to treatment and the development of side effects or toxicity.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma
Study Start Date : September 2001
Actual Primary Completion Date : December 2006
Actual Study Completion Date : September 2009



Intervention Details:
    Drug: Temozolomide
    Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half


Primary Outcome Measures :
  1. To determine the effects temozolomide has on low-grade gliomas [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. To determine whether temozolomide is effective in preventing or delaying future tumor growth [ Time Frame: 3 years ]
  2. to determine the safety of temozolomide [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological confirmation of a low-grade glioma (astrocytoma, oligodendroglioma, or mixed oligoastrocytoma)
  • Measurable disease on MRI
  • Patients that have undergone recent resection for newly diagnosed or recurrent or progressive tumor are eligible if they have recovered from the effects of surgery.
  • Patients with recurrent disease my have had one prior chemotherapy regimen
  • Older than 18 years of age.
  • Karnofsky performance status (KPS) performance score of > 70%
  • Adequate hematologic, renal and liver functions,
  • Life expectancy of greater than 12 weeks.
  • Negative pregnancy test.

Exclusion Criteria:

  • Prior treatment with temozolomide
  • Patients who are not neurologically stable
  • Acute infection treated with intravenous antibiotics
  • Non-malignant systemic disease
  • Frequent vomiting, inability to swallow or a medical condition that could interfere with oral medication.
  • Previous or concurrent malignancies at other sites, with the exception of surgically cured carcinoma in-situ of the cervix, and basal or squamous cell carcinoma of the skin.
  • HIV positive or AIDS-related illness
  • Pregnant or nursing women
  • Patients with allergy to decarbazine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00165360


Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
Schering-Plough
Brigham and Women's Hospital
University of Virginia
Investigators
Principal Investigator: Patrick Wen, MD Dana-Farber Cancer Institute

Responsible Party: Patrick Wen, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT00165360     History of Changes
Other Study ID Numbers: 01-111
First Posted: September 14, 2005    Key Record Dates
Last Update Posted: November 2, 2009
Last Verified: October 2009

Keywords provided by Dana-Farber Cancer Institute:
low-grade glioma
astrocytoma
oligodendroglioma
oligoastrocytoma
temozolomide
mixed oligoastrocytoma

Additional relevant MeSH terms:
Oligodendroglioma
Glioma
Astrocytoma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Dacarbazine
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents